19 recruiting, 8 completed, 5 unknown, 3 not yet recruiting. 17 Phase 2, 7 Phase 1, 6 Not applicable, 2 Phase 3, 1 Phase 4.
Follow this condition Literature Review of Myeloma Multiple trials Research Report on Myeloma Multiple
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma Etentamig, Isatuximab, Bortezomib + Lenalidomide + Dexamethasone - Myeloma Multiple, Myeloma | Phase 1 / Phase 2 | Not yet recruiting | Universitätsklinikum Hamburg-Eppendorf | 220 | 2026-12-01 | 2026-05-20 |
| A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple Myeloma CAR-T cells, BCMA bispecific - Myeloma Multiple | Phase 1 / Phase 2 | Not yet recruiting | Centre Hospitalier Universitaire de Saint Etienne | 44 | 2026-12-01 | 2026-10-09 |
| A Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (AMMADINA) BCD-248 + daratumumab, Daratumumab + pomalidomide + dexamethasone - Myeloma Multiple | Phase 3 | Recruiting | Biocad | 390 | 2026-06-15 | 2026-08-03 |
| Immune Fitness in Older Patients With Relapsed and Refractory Multiple Myeloma immunophenotyping of lymphocyte - Myeloma Multiple | Not applicable | Recruiting | Jules Bordet Institute | 31 | 2026-06-03 | 2026-06-29 |
| Infectious Complications in Hematological Patients Under Treatment With Bispecific Antibodies. Lymphoma Neoplasms, Myeloma Multiple | Recruiting | Infanta Leonor University Hospital | 350 | 2026-05-14 | 2026-05-27 | |
| Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure Cyclophosphamide, Bortezomib (VELCADE), Dexamethasone - Myeloma Multiple | Phase 2 | Recruiting | Eastern Cooperative Oncology Group | 74 | 2026-03-05 | 2026-09-14 |
| e-Motion : Promoting Emotion Regulation in Chronic Cancer Guided Self-Help intervention, Group and Guided Self-Help intervention - Metastatic Cancers, Myeloma Multiple | Not applicable | Recruiting | Université Libre de Bruxelles | 30 | 2025-11-20 | 2025-11-21 |
| MMAPPIN' Study: Multiple Myeloma Analysis For Patient-specific Insights to Dissect Disease Heterogeneity Myeloma Multiple | Recruiting | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 520 | 2025-10-15 | 2026-05-12 | |
| Determine the Frequency of Variants in the GBA/PSAP Genes in Patients With MM or MGUS Evaluation of the presence and number of mutated alleles of the GBA/PSAP genes in patients with MM or MGUS - Monoclonal Gammopathy of Undetermined Significance, Myeloma Multiple | Recruiting | University Hospital, Rouen | 300 | 2025-10-07 | 2026-06-10 | |
| Evaluation of the Role of Connected Scales in the Therapeutic Care of Hematology Patients Connected scale "Body Comp Pro" from Withings - Lymphoma, Non-Hodgkin, Myeloma Multiple | Not applicable | Recruiting | Assistance Publique - Hôpitaux de Paris | 30 | 2025-09-04 | 2025-09-15 |
| Bioequivalence Studies of Dasatinib 100 Mg Dasatinib 100 MG - Myeloma Multiple | Phase 4 | Not yet recruiting | Centro de Atencion e Investigacion Medica | 46 | 2025-09-01 | 2025-02-12 |
| A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma KLN-1010 - Multiple Myeloma in Relapse, Myeloma Multiple | Phase 1 | Recruiting | Kelonia Therapeutics, Inc. | 70 | 2025-07-16 | 2026-08-28 |
| Anonymization of Clinical Data From Pseudonymized Databases Collected as Part of Previus Clinical Trials on Multiple Myeloma Myeloma Multiple | Recruiting | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 600 | 2025-06-30 | 2026-05-12 | |
| Feasibility of a Multi-omics Platform for Hematological Malignancies Multi-omics analyses, Functional tests - Myeloma Multiple, Chronic Leukemia | Not applicable | Recruiting | Azienda Ospedaliero-Universitaria di Parma | 1040 | 2025-03-31 | 2026-03-03 |
| The Norwegian Immunotherapy in Multiple Myeloma Study Teclistamab, Elranatamab, Ciltacabtagene Autoleucel - Myeloma Multiple, Plasma Cell Leukemia | Recruiting | St. Olavs Hospital | 400 | 2025-01-15 | 2026-07-20 | |
| Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial Riluzole, Placebo - Breast Cancer, Sarcoma | Phase 2 | Recruiting | University of California, Irvine | 75 | 2024-12-02 | 2026-07-14 |
| Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma Bortezomib-bendamustine-melphalan - Myeloma Multiple | Recruiting | Uppsala University | 100 | 2024-11-24 | 2024-11-29 | |
| The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors CAR-T Cells infusion（CAR2219,CAR2019, CAR19 etc） - Lymphoma, B-cell, Aggressive Non-Hodgkin (B-NHL), AML (Acute Myelogenous Leukemia) | Phase 1 / Phase 2 | Recruiting | Tianjin Medical University General Hospital | 90 | 2024-11-09 | 2025-04-04 |
| Evaluation of a Range of Dermo-cosmetic Products to Treat Skin and Nail Toxicity Linked to Bispecific Anti-GPRC5D Bispecific Antibodies in Multiple Myeloma Patients". Myeloma". Descriptive Pilot Study dermo-cosmetic product - Myeloma Multiple | Not applicable | Completed | Nantes University Hospital | 20 | 2024-07-04 | 2026-04-16 |
| Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide and Dexamethasone in the Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma Drug and medical device - Multiple Myeloma, Myeloma Multiple | Not applicable | Active not recruiting | Poitiers University Hospital | 74 | 2023-10-23 | 2026-04-30 |
Showing 20 of 41. Sign in to see all of them.
Multiple Myeloma (41) · Neoplasms, Plasma Cell (8) · Lymphoma (5) · Neoplasms (4) · Hematologic Neoplasms (2) · Infections (2) · Leukemia (2) · Liver Neoplasms (2) · Lymphoma, Non-Hodgkin (2) · Lymphoproliferative Disorders (2) · Pancreatic Neoplasms (2) · Recurrence (2) · Blood Protein Disorders (1) · Bone Neoplasms (1) · Brain Neoplasms (1)
Cardiovascular Diseases (41) · Hemic and Lymphatic Diseases (41) · Hemorrhagic Disorders (41) · Blood Protein Disorders (40) · Hematologic Diseases (40) · Hemostatic Disorders (40) · Immune System Diseases (40) · Immunoproliferative Disorders (40) · Neoplasms by Histologic Type (40) · Paraproteinemias (40) · Vascular Diseases (40) · Lymphoproliferative Disorders (39) · Neoplasms (37) · Neoplasms, Plasma Cell (33) · Lymphatic Diseases (9)
Dexamethasone (7) · Lenalidomide (5) · Bortezomib (4) · daratumumab (4) · pomalidomide (3) · Cyclophosphamide (2) · carfilzomib (2) · selinexor (2) · Ascorbic Acid (1) · Bevacizumab (1) · Calcium Dobesilate (1) · Cannabidiol (1) · Clarithromycin (1) · Dasatinib (1) · Drugs, Generic (1)
Centre Hospitalier Universitaire de Saint Etienne (2) · IRCCS Azienda Ospedaliero-Universitaria di Bologna (2) · Nantes University Hospital (2) · Tel-Aviv Sourasky Medical Center (2) · Uppsala University (2) · AHS Cancer Control Alberta (1) · Abramson Cancer Center at Penn Medicine (1) · Assistance Publique - Hôpitaux de Paris (1) · Azienda Ospedaliera Universitaria Senese (1) · Azienda Ospedaliero-Universitaria di Parma (1) · Biocad (1) · Cartesian Therapeutics (1) · Centro de Atencion e Investigacion Medica (1) · Eastern Cooperative Oncology Group (1) · Hospital Universitario Dr. Jose E. Gonzalez (1)
United States (10) · France (9) · Italy (4) · Belgium (2) · Canada (2) · Russia (2) · Spain (2) · Sweden (2) · Australia (1) · Belarus (1) · China (1) · Colombia (1) · Germany (1) · Israel (1) · Malaysia (1)
Alessandro Gozzetti, Medicine (1) · Alexandre Chan, PharmD, MPH (1) · Alfred Garfall, MD (1) · Amany Keruakous (1) · Arina Zinkina (1) · Cesar H Gutierrez Aguirre (1) · Florence Lewis, PhD (1) · Gerard Bos (1) · Honar Cherif, MD, Ass prof (1) · Honar Cherif, MD, PhD (1) · Isabelle Merckaert, Professor (1) · Jason Tay, MD (1)
PMID 15880129, PMID 21532851, PMID 21542449, PMID 21622762, PMID 22106690, PMID 22373458, PMID 23244672, PMID 25909835, PMID 28912923, PMID 30828150, PMID 32909953, PMID 33619369, PMID 35285981, PMID 39608453, PMID 40629516, PMID 4305950
2018 (2), 2025 (2), 2023 (1)